Allabio’s viral tools portfolio focuses on lentiviral and AAV-based systems designed not merely for experimental success, but for continuity. Vector architecture, packaging logic, and quality attributes are shaped with downstream development in mind, allowing research teams to progress without repeatedly re-engineering their foundations. These tools act as quiet infrastructure—supporting gene therapy, cell therapy, and functional genomics programs that demand consistency rather than improvisation.
In parallel, the exosome portfolio—developed in close collaboration with EVMed—brings industrial order to one of biology’s most elegant messengers. Covering isolation, purification, detection, and characterization, this category transforms exosomes from delicate research objects into standardized biological materials. The emphasis is not speculative promise, but reproducibility: enabling credible biomarker research, diagnostic exploration, and early delivery concepts.